ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ALX ONCOLOGY HOLDINGS INC.
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/08ALX ONCOLOGY : Reports Second Quarter 2022 Financial Results and Provides Clinical Develop..
PU
08/08ALX ONCOLOGY : Corporate Presentation
PU
08/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
AQ
06/16ALX ONCOLOGY HOLDINGS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/07ALX ONCOLOGY : Corporate Presentation
PU
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/01ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
GL
05/09ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
GL
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
04/12ALX ONCOLOGY : Appoints Itziar Canamasas, Ph.D., to its Board of Directors - Form 8-K
PU
04/12ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K)
AQ
04/12ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
GL
03/25ALX ONCOLOGY : Corporate Presentation
PU
03/02ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept..
GL
02/28ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
02/28ALX ONCOLOGY : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Cl..
PU
02/28ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C..
AQ
01/27ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
01/27ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
01/18ALX ONCOLOGY : Corporate Presentation
PU
01/10ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
GL
01/10ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
GL
01/04ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ALX ONCOLOGY HOLDINGS INC : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
2021DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Ind..
PR
2021ALX ONCOLOGY : ASH Conference Call Presentation
PU
2021ALX ONCOLOGY : Corporate Presentation
PU
2021ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evo..
AQ
2021ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
2021ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Develop..
PU
2021ALX Oncology Corporate Presentation
PU
2021ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Develop..
GL
2021ALX Oncology SITC Conference Call Presentation
PU
2021ALX Oncology Corporate Presentation, November 9, 2021
PU
2021ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpace..
GL
2021ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 6..
GL
2021ALX Oncology Announces Upcoming Virtual Investor Conference Participation
AQ
2021ALX ONCOLOGY : Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept ..
GL
2021ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio (Form 8-..
PU
2021ALX ONCOLOGY HOLDINGS INC : Unregistered Sale of Equity Securities, Other Events, Financia..
AQ
2021ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
AQ
2021ALX ONCOLOGY : Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clini..
PU
2021ALX ONCOLOGY : Corporate Presentation, October 5, 2021
PU
2021ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immu..
GL
2021ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148..
GL
2021ALX ONCOLOGY : Announces Upcoming Virtual Investor Conference Participation
AQ
2021ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K)
AQ
2021ALX ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
2021ALX ONCOLOGY : Reports Second Quarter 2021 Financial Results and Provides Clinical Develop..
PU
2021ALX ONCOLOGY : Corporate Presentation, August 12, 2021
PU
2021ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Develo..
GL
2021ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Co..
GL
2021ALX ONCOLOGY : Corporate Presentation, July 16, 2021
PU
2021ALX ONCOLOGY : ESMO GI Presentation
PU
2021ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Ro..
GL
2021ALX ONCOLOGY HOLDINGS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Nec..
GL
2021ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), ..
GL
2021ALX Oncology Announces Upcoming Virtual Investor Conference Participation
GL
2021ALX ONCOLOGY : Reports First Quarter 2021 Financial Results and Provides Clinical Developm..
PU
2021ALX ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
2021ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Develop..
GL
2021ALX ONCOLOGY : Corporate Presentation, May 17, 2021
PU
2021ALX ONCOLOGY : NYAS Presentation
PU
2021ALX ONCOLOGY : Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Com..
AQ
2021ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K)
AQ
1  2Next
Upcoming event on ALX ONCOLOGY HOLDINGS INC.